Johnson & Johnson (NYSE:JNJ - Get Free Report) shot up 1.5% on Monday . The stock traded as high as $169.90 and last traded at $169.16. 4,082,648 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 7,022,617 shares. The stock had previously closed at $166.69.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on JNJ shares. Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Bank of America raised their target price on Johnson & Johnson from $159.00 to $171.00 and gave the company a "neutral" rating in a report on Wednesday, March 5th. Finally, Morgan Stanley decreased their price target on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $171.33.
Read Our Latest Report on Johnson & Johnson
Johnson & Johnson Price Performance
The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market cap of $399.33 billion, a price-to-earnings ratio of 24.94, a PEG ratio of 2.56 and a beta of 0.47. The company has a 50 day simple moving average of $153.86 and a 200-day simple moving average of $156.29.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm's revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.29 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 2.99%. Johnson & Johnson's payout ratio is currently 74.59%.
Insider Transactions at Johnson & Johnson
In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.
Institutional Investors Weigh In On Johnson & Johnson
Hedge funds have recently made changes to their positions in the business. Vinva Investment Management Ltd boosted its position in Johnson & Johnson by 6.8% during the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock worth $17,988,000 after acquiring an additional 7,110 shares during the period. Financial Counselors Inc. lifted its holdings in Johnson & Johnson by 5.3% in the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock worth $29,996,000 after purchasing an additional 9,309 shares during the period. Oregon Pacific Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at about $949,000. Horan Securities Inc. increased its stake in Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after buying an additional 90 shares during the period. Finally, Strategic Financial Concepts LLC raised its position in shares of Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock worth $501,000 after buying an additional 1,271 shares in the last quarter. Institutional investors own 69.55% of the company's stock.
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
